DK3969117T3 - Krystallinske former af n-[4-(chlordifluormethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridin-3-carboxamid - Google Patents
Krystallinske former af n-[4-(chlordifluormethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridin-3-carboxamidInfo
- Publication number
- DK3969117T3 DK3969117T3 DK20726959.8T DK20726959T DK3969117T3 DK 3969117 T3 DK3969117 T3 DK 3969117T3 DK 20726959 T DK20726959 T DK 20726959T DK 3969117 T3 DK3969117 T3 DK 3969117T3
- Authority
- DK
- Denmark
- Prior art keywords
- chlorodifluormethoxy
- hydroxypyrrolidin
- pyrazol
- carboxamide
- pyridin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962848857P | 2019-05-16 | 2019-05-16 | |
| US201962949599P | 2019-12-18 | 2019-12-18 | |
| PCT/IB2020/054628 WO2020230099A1 (en) | 2019-05-16 | 2020-05-15 | Crystalline forms of n-[4-(chlorodifluoromethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3969117T3 true DK3969117T3 (da) | 2026-05-26 |
Family
ID=70775449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20726959.8T DK3969117T3 (da) | 2019-05-16 | 2020-05-15 | Krystallinske former af n-[4-(chlordifluormethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridin-3-carboxamid |
Country Status (22)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202444706A (zh) | 2019-05-16 | 2024-11-16 | 瑞士商諾華公司 | N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀 |
| EP4353230A3 (en) | 2020-01-28 | 2024-06-19 | Teva Pharmaceuticals International GmbH | Solid state forms of asciminib and process for preparation thereof |
| AU2021377336A1 (en) * | 2020-11-16 | 2023-07-06 | Prothera Biologics, Inc. | Methods for purifying inter-alpha inhibitor proteins |
| WO2022206937A1 (zh) * | 2021-04-01 | 2022-10-06 | 苏州晶云药物科技股份有限公司 | 一种吡唑取代的烟酰胺类化合物的盐酸盐新晶型及其制备方法 |
| CN114369085B (zh) * | 2021-12-27 | 2023-01-03 | 武汉九州钰民医药科技有限公司 | 盐酸Asciminib的制备方法 |
| EP4615831A1 (en) * | 2022-11-10 | 2025-09-17 | Synthon B.V. | Crystalline form of asciminib hydrochloride |
| WO2024257116A1 (en) * | 2023-06-13 | 2024-12-19 | Natco Pharma Limited | Novel polymorphic forms of asciminib and its pharmaceutical salts thereof |
| EP4758138A1 (en) * | 2023-08-07 | 2026-06-17 | Biophore India Pharmaceuticals Pvt. Ltd. | A process for the preparation of solid forms of n-[4(chlorodifluoromethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-3-yl) pyridine-3-carboxamide hydrogen chloride |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO4920215A1 (es) | 1997-02-14 | 2000-05-29 | Novartis Ag | Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones |
| IL150524A0 (en) | 2000-01-07 | 2003-02-12 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| KR20150008406A (ko) | 2012-05-15 | 2015-01-22 | 노파르티스 아게 | Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체 |
| ES2670601T3 (es) * | 2012-05-15 | 2018-05-31 | Novartis Ag | Derivados de benzamida para la inhibición de la actividad de ABL1, ABL2 y BCR-ABL1 |
| MX2015008427A (es) | 2012-12-27 | 2015-10-22 | Zentiva Saglik Ürünleri San Ve Tic A S | Proceso de granulacion en seco para producir composiciones de comprimidos de metformina y sus composiciones. |
| SG10201900648SA (en) | 2014-07-25 | 2019-02-27 | Novartis Ag | Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide |
| EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
| EP3120851A1 (en) | 2015-07-21 | 2017-01-25 | Pangaea Biotech S.L. | 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers |
| US9931342B2 (en) | 2016-02-02 | 2018-04-03 | Duke University | Compositions and methods for the treatment of cancer |
| EP3292870A1 (en) | 2016-09-08 | 2018-03-14 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Fibronectin for use in the treatment of leukemia |
| US20200017482A1 (en) | 2016-09-27 | 2020-01-16 | Novartis Ag | Surfactant systems for crystallization of organic compounds |
| WO2019084499A1 (en) | 2017-10-27 | 2019-05-02 | Genea Biocells USA (Holdings), Inc. | INHIBITORS OF DUX4 INDUCTION FOR REGULATION OF MUSCLE FUNCTION |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| TW202444706A (zh) | 2019-05-16 | 2024-11-16 | 瑞士商諾華公司 | N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀 |
-
2020
- 2020-05-14 TW TW113128176A patent/TW202444706A/zh unknown
- 2020-05-14 TW TW109116067A patent/TWI853027B/zh active
- 2020-05-14 US US16/874,622 patent/US11407735B2/en active Active
- 2020-05-15 BR BR112021022712A patent/BR112021022712A2/pt unknown
- 2020-05-15 ES ES20726959T patent/ES3070743T3/es active Active
- 2020-05-15 EP EP26166153.2A patent/EP4775572A2/en active Pending
- 2020-05-15 PL PL20726959.8T patent/PL3969117T3/pl unknown
- 2020-05-15 MX MX2021013970A patent/MX2021013970A/es unknown
- 2020-05-15 HR HRP20260615TT patent/HRP20260615T1/hr unknown
- 2020-05-15 WO PCT/IB2020/054628 patent/WO2020230099A1/en not_active Ceased
- 2020-05-15 CN CN202080051576.4A patent/CN114144232A/zh active Pending
- 2020-05-15 JP JP2021568319A patent/JP2022532404A/ja not_active Withdrawn
- 2020-05-15 DK DK20726959.8T patent/DK3969117T3/da active
- 2020-05-15 KR KR1020217040723A patent/KR102945602B1/ko active Active
- 2020-05-15 EP EP20726959.8A patent/EP3969117B1/en active Active
- 2020-05-15 PT PT207269598T patent/PT3969117T/pt unknown
- 2020-05-15 LT LTEPPCT/IB2020/054628T patent/LT3969117T/lt unknown
- 2020-05-15 RS RS20260555A patent/RS68078B1/sr unknown
- 2020-05-15 SI SI202030769T patent/SI3969117T1/sl unknown
- 2020-05-15 FI FIEP20726959.8T patent/FI3969117T3/fi active
- 2020-05-15 KR KR1020267009222A patent/KR20260055492A/ko active Pending
- 2020-05-15 CA CA3139812A patent/CA3139812A1/en active Pending
- 2020-05-15 AU AU2020276701A patent/AU2020276701B2/en active Active
-
2021
- 2021-11-10 IL IL287995A patent/IL287995A/en unknown
- 2021-11-15 CL CL2021003011A patent/CL2021003011A1/es unknown
-
2022
- 2022-07-06 US US17/858,701 patent/US12252478B2/en active Active
- 2022-07-06 US US17/858,713 patent/US12252479B2/en active Active
-
2024
- 2024-03-21 JP JP2024045596A patent/JP2024095697A/ja active Pending
-
2026
- 2026-01-15 JP JP2026005366A patent/JP2026086446A/ja active Pending